x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

39:57

53. Ductal carcinoma in situ (DCIS) and Lobular...

Oncology for the Inquisitive Mind ·

2023/07/15

DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in situ) are challenging areas of breast cancer oncology. Michael and Josh return from their short hiatus to find their podcast has been ranked one of the top oncology podcasts by feedspot. Do not fear; they won't rest on their laurels and are ready to roll and bring another exciting episode of management, intrigue, and choose your adventure. Neither DCIS nor LCIS are technically cancer, but they both have the propensity to develop into a

en

24:25

52. ASCO 2023 - Plenary Session

Oncology for the Inquisitive Mind ·

2023/06/13

Theodore Roosevelt is famously quoted saying: "It is hard to fail, but it is worse never to have tried to succeed."This is what ASCO, oncologists and cancer researchers are faced with daily. As our tour de force of ASCO 2023 ends, and we foresee a future where daily episodes don't arrive, we present our final episode. Michael and Josh have kept three of the most exciting trials until the end.Today, three plenary sessions are reviewed. The first is in gliomas, the second in adjuvant lung cancer

en

27:00

51. ASCO 2023 - Melanoma & Head and Neck

Oncology for the Inquisitive Mind ·

2023/06/12

The epic journey of Josh and Michael across tumour streams at ASCO 2023 is approaching its end. It has been a whirlwind tour through groundbreaking science, hazard ratios and exciting glimpses into a brighter future for cancer patients. However, our intrepid duo's work is not yet done, merely reached its penultimate stage. In today's episode, Josh and Michael examine four notable studies in the spheres of melanoma and head and neck cancer. Spoiler alert: in this part of the map, here there be

en

22:13

50. ASCO 2023 - Metastatic NSCLC

Oncology for the Inquisitive Mind ·

2023/06/11

Every epic journey has that moment when the end is in sight. The start of the last lap of the race, the final dramatic encounter with the main villain. On this episode of Oncology for the Inquisitive Mind, that villain is metastatic lung cancer, with a particular focus on EGFR mutant disease. There have been a lot of questions raised about the best next step after the failure of the star of ASCO 2023: osimertinib. Here, Josh and Michael examine three breaking studies that seek to shed some light on

en

21:06

49. ASCO 2023 - Metastatic Breast Cancer

Oncology for the Inquisitive Mind ·

2023/06/10

Cancer is facing a seismic shift as precision oncology is becoming a reality, and adoption is skyrocketing as new anti-cancer agents are released. It appears that the days of blunt-force chemotherapy could be limited. Paul Ehrlich, the German Chemist, is credited with the term "chemotherapy", but more importantly, the concept of the magic bullet, "zauberkugel", which would allow selective targeting of pathogenic microbes without affecting other parts of the body. Leading the field of targeting

en

30:03

48. ASCO 2023 - Prostate, Bladder and Renal Cancer

Oncology for the Inquisitive Mind ·

2023/06/09

ASCO 23 explored novel anti-cancer agents in the genitourinary space. The future of oncology is etching closer daily. In this episode, Michael and Josh dissect ertafitinib, an FGFR inhibitor used in bladder cancer, talazoparib in prostate cancer and immunotherapy and TKI combinations in renal cell cancer. All these studies reflect the desire to target cancers further with some astonishing results. StudiesTHOR: https://meetings.asco.org/abstracts-presentations/217894PEACE-1:

en

22:20

47. ASCO 2023 - Colorectal Cancer

Oncology for the Inquisitive Mind ·

2023/06/08

ASCO 2023 has been an incredible journey, and the latest instalment of Michael and Josh's search for the latest and greatest oncological news is no exception. On this episode, our intrepid duo examine three studies with potentially practice-changing consequences, like Burton and Speke quest for the source of the River Nile. Which, in this ASCO series is literally just another day at the office. But will the presented evidence live up to the promise provided by its premise? You'll have to listen on

en

22:34

46. ASCO 2023 - Early Lung Cancer

Oncology for the Inquisitive Mind ·

2023/06/07

In this episode, Michael and Josh investigate Lung Oncology research presented at ASCO 23, specifically early lung cancer treatment. They discuss Perioperative Toripalimab, LAG3 inhibitor Relatlimab and the new novel agent BI 764532, a novel DLL3-targeting T cell engaged.Studies:NEOTORCH: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.36_suppl.425126NEOPREDICT: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.8500DLL3-positive SCLC:

en

34:30

45. ASCO 2023 - Gynaecologic Cancers

Oncology for the Inquisitive Mind ·

2023/06/06

Ovarian, cervical and endometrial cancer need more treatment options. Platinum-based chemotherapy only works for so long. ASCO 23 delivers with the practice-changing MIRASOL study introducing Mirvetuximab Soravtansine, a novel ADC with efficacy in ovarian cancer. Michael and Josh also discuss the Oval Study (ofranergene obadenovec) and immunotherapy in the DUO-O trial and Keynote 826. Not all trials are equal, and this OftIM ASCO special explores endpoints, hazard ratios and comparisons.Stay tuned

en

26:48

44. ASCO 2023 - Central Nervous System

Oncology for the Inquisitive Mind ·

2023/06/05

Captain's Log: ASCO Day 3.Today's episode brought myriad developments in treating CNS cancers and brain metastases from other distant lands. Some studies offered new and exciting targets for potential treatments. Others purported to provide benefits in new and exciting ways, eschewing infusions and tablets with vaccinations. Still, others repurposed old technology in new ways, investigating uses for things we already had.Unfortunately, many of the solutions were premature and primitive in their

en

33:10

43. ASCO 2023 - Early Hormone Receptor Positive...

Oncology for the Inquisitive Mind ·

2023/06/04

Hormone receptor-positive breast cancer again takes centre stage at the ASCO 23 (American Society of Clinical Oncology) Annual Meeting and has reinvented itself over the last two decades. Improvements are occurring in the adjuvant and neoadjuvant setting for both estrogen (ER) and progesterone (PR) positive and the human epidermal growth factor receptor space (HER2). In this episode, Michael and Josh take a closer look at MonarchE (Abemaciclib), NATALEE (Ribociclib), PHERgain (dose de-escalation)

en

30:05

42. ASCO 2023 - Gastroesophageal, Pancreatic and...

Oncology for the Inquisitive Mind ·

2023/06/04

ASCO 23 (American Society of Clinical Oncology) Annual Meeting in Chicago showcased a plethora of cutting-edge trials and research. Upper gastrointestinal cancers such as gastric, pancreatic and hepatobiliary are usually relegated to the backstage, but this year, several exciting and potentially practice-changing studies (not without their limitations).We explore a new PD-1Toripalimab in gastric and gastroesophageal cancer, liposomal irinotecan in NALIRIFOX versus gemcitabine/abraxane in metastatic

en

20:52

41. Pre-ASCO Appetizer

Oncology for the Inquisitive Mind ·

2023/06/02

*SPECIAL EPISODE ALERT*Every year, Josh and Mike cross their fingers and pray to Father Conference-Leave that they can make the pilgrimage to one of the two central sites of Oncology: Madrid for ESMO or Chicago for ASCO. Unfortunately, to this point, Father Conference-Leave has not delivered, and 2023 is no different. However, the cold and wind will not stop our intrepid hosts from parsing the avalanche of potentially practice-changing studies, agents and professional development about to descend on

en

22:32

OncoSnacks 8: Chemotherapy-induced Peripheral Neuropathy

Oncology for the Inquisitive Mind ·

2023/05/30

Peripheral neuropathy is a common toxicity of multiple anticancer agents used to treat and cure cancer, including platinum, taxanes and vinca alkaloids chemotherapy. These chemotherapy classes are as ubiquitous for cancer treatment as the sun is to plant photosynthesis. This week on OncoSnacks, Michael and Josh investigate what to do when a patient has peripheral neuropathy and examine existing evidence for prevention, treatment and duration of this sequelae.For more episodes, resources and blog

en

37:29

40. Advanced Endometrial Cancer

Oncology for the Inquisitive Mind ·

2023/05/27

It is always nice to be able to say the phrase: "This cancer has an excellent prognosis." That is the case with endometrial cancer, which for the majority of sufferers, can be cured and carries an excellent survival. However, there are cases that unfortunately present late, and for these patients, the outlook is significantly more grim.Some oncologists have little experience treating advanced endometrial cancer; for those listeners, this episode is specifically for you! In our 40th episode, Josh

en

49:50

39. Leadership, Policy and Teletrials with Prof Sabe...

Oncology for the Inquisitive Mind ·

2023/05/20

COSA President-elect (Clinical Oncology Society Australia), Professor Sabe Sabesan, is the oncologist and doctor we all dreamed of being when starting our medical training. This is a story of adversity, compassion and drive without compromise. Sabe's global journey has taken him to some of the remotest places on earth, with each inflection point creating new challenges and opportunities. We discuss advocacy, the rollout of teletrials to improve equitable access, redefining system issues with the

en

18:46

OncoSnacks 7: Cardiotoxicity with Dr Mark Nolan

Oncology for the Inquisitive Mind ·

2023/05/16

On Oncology for the Inquisitive Mind, we like to focus on cancer and available treatment options. However, every oncologist is at his or her best when working hand-in-hand with other specialities. In this, our seventh episode of OncoSnacks, Michael and Josh interview Dr Mark Nolan, a non-invasive cardiologist with a special interest in anti-cancer treatment-induced cardiotoxicity. Mark provides an engaging, comprehensive overview of the diagnosis and management of cardiotoxicity, with a particular

en

27:20

38. Adenoid Cystic Carcinoma - Rare Cancer Snapshot

Oncology for the Inquisitive Mind ·

2023/05/13

Adenoid Cystic Carcinoma (ACC) is a rare cancer commonly found in the head and neck region, arising from glandular salivary tissue. Like many orphan cancers, effective treatments in the metastatic setting are needed desperately. The 5-year survival rate is 80% and declines over time. In this special subseries: Rare Cancer Snapshots, Michael and Josh pour over the evidence for ACC, pathophysiology and the treatment paradigm to date.For more episodes, resources and blog posts, visit

en

44:03

37. Metastatic Castrate Resistant Prostate Cancer-...

Oncology for the Inquisitive Mind ·

2023/05/06

Lutetium PSMA (Lutetium-177), theranostic medicineand future advances in prostate cancer are coming to an oncology centre near you faster than you can say "novel drug development" and "progression-free survival". This week Michael and Josh conclude their epic prostate cancer trilogy by exploring theranostic medicine and radioactive drug development while looking at the past of the cytotoxic world and the role of cabazitaxel. To ensure we keep your attention, six trials are discussed today, and a

en

42:38

36. Early Drug Development and Mentorship with Dr...

Oncology for the Inquisitive Mind ·

2023/04/29

Every feast needs a palate cleanser. Every great work of theatre needs an intermission. Every sports event needs a half-time show. In this way, Oncology for the Inquisitive Mind is no different to Hamilton or the Super Bowl. Here, we provide a little deviation from our ongoing Prostate Cancer Saga to interview Dr Jenny Liu, Oncologist and early drug development (EDD) researcher extraordinaire. Our discussions range from her slightly unusual path to oncology, her previous research and how it is still

en

202 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown